[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343947-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343947-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","socs1-a-potential-diagnostic-and-prognostic-marker-for-aggressive-gliomas-and-a-new-target-for-immunotherapy","SOCS1: A potential diagnostic and prognostic marker for aggressive gliomas and a new target for immunotherapy","","Gliomas are common and lethal central nervous system cancers that create an immunological barrier reducing immunotherapy effectiveness. Suppressor of cytokine signaling 1 (SOCS1), abundant in high-grade gliomas, is examined as both a biomarker and an immunotherapy target. Comparative analyses between SOCS1 and glioma immune checkpoints are combined with comprehensive gene-expression profiling and clinical data validation. A predictive prognostic model is built to confirm SOCS1’s diagnostic and prognostic value, showing SOCS1 similarity to checkpoints like CTLA4. Incorporating SOCS1 improves model accuracy and suggests strategies to overcome glioma immune suppression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/socs1-a-potential-diagnostic-and-prognostic-marker-for-aggressive-gliomas-and-a-new-target-for-immunotherapy/343947/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/socs1-a-potential-diagnostic-and-prognostic-marker-for-aggressive-gliomas-and-a-new-target-for-immunotherapy/343947.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is SOCS1 and why is it relevant to aggressive gliomas?","Question",{"text":63,"@type":64},"SOCS1 is a suppressor of cytokine signaling protein family member that is abundant in high-grade gliomas and is evaluated as a diagnostic and prognostic biomarker and potential immunotherapy target.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the study compare SOCS1 with glioma immune checkpoints?",{"text":68,"@type":64},"The study performs comparative analyses of SOCS1 against various glioma immune checkpoints and evaluates similarities, including links to checkpoints such as CTLA4.",{"name":70,"@type":61,"acceptedAnswer":71},"How is SOCS1 used to improve prognostic prediction?",{"text":72,"@type":64},"Clinical patient information is used to construct a bespoke predictive model; adding SOCS1 significantly enhances prognostic accuracy and supports its role as an independent prognostic factor.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343947,1790335508,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","®  \n Observational Study   \nSOCS1: A potential diagnostic and prognostic marker for aggressive gliomas and a new target for immunotherapy  \nChuanshen Gu, BMa ,b , Xinyi Chen, BMc , Jiayan Wu, BMa ,b , Yiwen Zhang, BMa ,b , Linyu Zhong, BMa ,b , Han Luo, BMd , Wenshu Luo, MDa ,b ,* , Fuxia Yang, MDa ,b  \n\n| Abstract\u003Cbr>Gliomas, the most common and deadly cancers of the central nervous system, present a unique immunological barrier that severely undermines the effectiveness of immunotherapies. Suppressor of cytokine signaling 1 (SOCS1), belonging to the SOCS protein family and playing a pivotal role in various cancer treatment strategies and is abundant in high-grade gliomas. This study conducted a comparative analysis of SOCS1 and glioma immune checkpoints. It underscores the feasibility of leveraging SOCS1 as a promising diagnostic and prognostic marker for aggressive gliomas, thus offering novel targets for glioma immunotherapy. Comprehensive gene expression analyses and clinical data validations were performed across multiple databases. The expression and biological functions of SOCS1 were examined through an array of techniques including pan-cancer analysis, functional enrichment, gene set variation analysis, and immune microenvironment examination. This was done alongside a comparison of the similarities between SOCS1 and various glioma immune checkpoints. Utilizing clinical information from patients, a bespoke predictive model was developed to further corroborate the prognostic capabilities of SOCS1 . The investigation revealed considerable similarities between SOCS1 and several immune checkpoints such as CTLA4, demonstrating SOCS1’s role as an independent prognostic factor positively influencing glioma patient outcomes. The inclusion of SOCS1 in the developed predictive model significantly enhanced its precision. Our findings highlight SOCS1’s potential as an innovative target for glioma immunotherapy, providing a novel strategy to overcome the immunological barriers posed by gliomas. Furthermore, identifying SOCS1 as a viable diagnostic marker for aggressive gliomas improves the accuracy of prognostic predictions for affected patients. |\n| --- |\n| Abbreviations: AUC = area under the curve, CGGA = Chinese Glioma Genome Atlas, GBM = glioblastoma multiforme, GEO = Gene Expression Omnibus, GO = Gene Ontology, GSEA = gene set enrichment analysis, GSVA = gene set variation analysis, GTEx = genotype-tissue expression, IDH = isocitrate dehydrogenase, KEGG = Kyoto Encyclopedia of Genes and Genomes, LGG = low grade glioma, MSI = microsatellite instability, ROC = receiver operating characteristic, SOCS1 = suppressor of cytokine signaling 1, ssGSEA = single-sample gene set enrichment analysis, TCGA = the Cancer Genome Atlas, TMB = tumor mutation burden, WHO = World Health Organization. |\n| Keywords: glioma, immune checkpoint, personalized prognosis model, prognostic prediction, SOCS1 |\n\n1. Introduction  \nGliomas represent the predominant form of primary malignant tumors within the adult central nervous system,[1,2] notable for their aggressive growth, invasive proliferation, and propensity for recurrence. The World Health Organization (WHO) categorizes gliomas into 4 grades, among which glioblastoma (WHO  \nIV), a variant known for its chemoresistance, comprises about 50% of all glioma incidences.[3] Despite recent advances in glioma treatment modalities, the overall prognosis for the majority of patients remains grim.[4–6]  \nImmunotherapy, especially strategies involving immune checkpoint inhibitors and adoptive cell transfer, has demonstrated effectiveness against a broad range of tumors. [7] Yet,  \nThis study was supported by grants from the Scientific Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine (20231283), Shenzhen Science and Technology Program (JCYJ20210324111201005),  \nShenzhen Science and Technology R&D Funding Program Key Laboratory Project (CXB201111250113A), Sanming Project of Medicine ","cbCaiaIlEHl9jrcm","https://ap.wps.com/l/cbCaiaIlEHl9jrcm","pdf",6126407,18,"English","# Abstract\n# Abbreviations\n# Introduction","[{\"question\":\"What is SOCS1 and why is it relevant to aggressive gliomas?\",\"answer\":\"SOCS1 is a suppressor of cytokine signaling protein family member that is abundant in high-grade gliomas and is evaluated as a diagnostic and prognostic biomarker and potential immunotherapy target.\"},{\"question\":\"How does the study compare SOCS1 with glioma immune checkpoints?\",\"answer\":\"The study performs comparative analyses of SOCS1 against various glioma immune checkpoints and evaluates similarities, including links to checkpoints such as CTLA4.\"},{\"question\":\"How is SOCS1 used to improve prognostic prediction?\",\"answer\":\"Clinical patient information is used to construct a bespoke predictive model; adding SOCS1 significantly enhances prognostic accuracy and supports its role as an independent prognostic factor.\"}]","SOCS1: A potential diagnostic and prognostic marker for aggressive gliomas and a new target for immunotherapy | PDF",1790052597,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2ef3aff3645b296860b482346692b04.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80955c159fa10c2de9f0224348dedd1a.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/222242be3098526abb2d2087dfa91300.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4324284351f7116c399339f398df5d6.webp",980,1306]